Alagebrijum

Alagebrijum
(IUPAC) ime
	4,5-dimetil-3-(2-okso-2-feniletil)-tiazolijum hlorid
Klinički podaci
Identifikatori
CAS broj	341028-37-3
ATC kod	nije dodeljen
PubChem	216306
ChemSpider	187495
UNII	DGH49JXB1F
Hemijski podaci
Formula	C13H14ClNOS
Mol. masa	267,774 g/mol
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C13H14NOS.ClH/c1-10-11(2)16-9-14(10)8-13(15)12-6-4-3-5-7-12;/h3-7,9H,8H2,1-2H3;1H/q+1;/p-1 ; Key: MKOMESMZHZNBIZ-UHFFFAOYSA-M
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

Alagebrijum (ALT-711) je potencijalni lek. On je bio prvi kandidat leka koji je klinički testiran kao sredstvo za raskidanje umrežavanja uzrokovanog krajnjim proizvodima uznapredovale glikacije, čime se poništava jedan od glavnih mehanizama starenja.^[4] Alagebrium je dizajniran da na taj način preokreće očvršćavanje zidova krvnih sudova, što doprinosi hipertenziji i kardiovaskularnim bolestima, kao i mnogim drugim formama degradacije vezanim za umrežavanje proteina.^[5]^[6]^[7] Pokazano je da je alagebrijum efektivan u redukovanju sistolnog krvnog pritiska^[8] i da je terapeutski koristan kod pacijenata sa dijastolnim zatajenjem srca.^[9]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ „R&D overview: A.G.E. crosslink breakers and Alagebrium”. Alteon Corporation. Arhivirano iz originala na datum 2007-07-01. Pristupljeno 2007-07-04.
↑ „Product Candidate: A.G.E. crosslink breakers”. Alteon Corporation. Arhivirano iz originala na datum 2007-07-01. Pristupljeno 4. 7. 2007.
↑ Lisa Melton (June 2000). AGEing – breaking the bonds. Novartis Foundation Bulletin. Arhivirano iz originala na datum 2007-08-06. Pristupljeno 2007-07-04.
↑ Carmia Borek (Aug 2001). Age breakers. Life Extension Magazine. Pristupljeno 2007-07-04.
↑ Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S (2004). „Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process”. American Journal of Hypertension 17 (12 Pt 2): 23S–30S. DOI:10.1016/j.amjhyper.2004.08.022. PMID 15607432.
↑ Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC (2005). „The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure”. Journal of Cardiac Failure 11 (3): 191–195. DOI:10.1016/j.cardfail.2004.09.010. PMID 15812746.

Povezano

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[alteonr&d-4] „R&D overview: A.G.E. crosslink breakers and Alagebrium”. Alteon Corporation. Arhivirano iz originala na datum 2007-07-01. Pristupljeno 2007-07-04.

[alteonr&d2-5] „Product Candidate: A.G.E. crosslink breakers”. Alteon Corporation. Arhivirano iz originala na datum 2007-07-01. Pristupljeno 4. 7. 2007.

[novartis-6] Lisa Melton (June 2000). AGEing – breaking the bonds. Novartis Foundation Bulletin. Arhivirano iz originala na datum 2007-08-06. Pristupljeno 2007-07-04.

[lef-7] Carmia Borek (Aug 2001). Age breakers. Life Extension Magazine. Pristupljeno 2007-07-04.

[8] Bakris GL, Bank AJ, Kass DA, Neutel JM, Preston RA, Oparil S (2004). „Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process”. American Journal of Hypertension 17 (12 Pt 2): 23S–30S. DOI:10.1016/j.amjhyper.2004.08.022. PMID 15607432.

[9] Little WC, Zile MR, Kitzman DW, Hundley WG, O'Brien TX, Degroof RC (2005). „The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure”. Journal of Cardiac Failure 11 (3): 191–195. DOI:10.1016/j.cardfail.2004.09.010. PMID 15812746.

[4]

[5]

[6]

[7]

[8]

[9]

[1]

[2]

[3]